TipRanks on MSN3d
FDA approves Johnson & Johnson’s TREMFYA in Crohn’s diseaseJohnson & Johnson announced that the FDA has approved TREMFYA, or guselkumab, the first and only IL-23 inhibitor offering ...
such as osteoclasts from monocytes/macrophages." In this study, the researchers constructed a light-activated form of RANK, an important signaling protein in osteoclast differentiation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback